# Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

> **NCT05416762** · PHASE1 · COMPLETED · sponsor: **Seasons Biotechnology (Taizhou) Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Major Depressive Disorder (MDD

## Interventions

- **DRUG:** Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
- **DRUG:** Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
- **DRUG:** Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg

## Key facts

- **NCT ID:** NCT05416762
- **Lead sponsor:** Seasons Biotechnology (Taizhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-19
- **Primary completion:** 2022-11-25
- **Final completion:** 2022-11-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05416762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05416762, "Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05416762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*